Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.
Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arłukowicz B, Wysocki P, Jankowski T, Radecka B, Foszczynska-Kłoda M, Litwiniuk M, Debska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Duchnowska R, et al. Among authors: sperinde j. Oncologist. 2012;17(1):26-35. doi: 10.1634/theoncologist.2011-0212. Epub 2012 Jan 10. Oncologist. 2012. PMID: 22234627 Free PMC article.
Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J. Duchnowska R, et al. Among authors: sperinde j. Clin Cancer Res. 2014 May 15;20(10):2805-13. doi: 10.1158/1078-0432.CCR-13-2782. Epub 2014 Mar 25. Clin Cancer Res. 2014. PMID: 24668646
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.
Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, Haddad M, Paquet A, Lie Y, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arłukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Biernat W, Jassem J. Duchnowska R, et al. Among authors: sperinde j. Neuro Oncol. 2015 Sep;17(9):1241-9. doi: 10.1093/neuonc/nov012. Epub 2015 Feb 13. Neuro Oncol. 2015. PMID: 25681308 Free PMC article.
Very high quantitative tumor HER2 content and outcome in early breast cancer.
Joensuu H, Sperinde J, Leinonen M, Huang W, Weidler J, Bono P, Kataja V, Kokko R, Turpeenniemi-Hujanen T, Jyrkkiö S, Isola J, Kellokumpu-Lehtinen PL, Paquet A, Lie Y, Bates M. Joensuu H, et al. Among authors: sperinde j. Ann Oncol. 2011 Sep;22(9):2007-2013. doi: 10.1093/annonc/mdq710. Epub 2011 Feb 1. Ann Oncol. 2011. PMID: 21285132 Free article. Clinical Trial.
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
Bates M, Sperinde J, Köstler WJ, Ali SM, Leitzel K, Fuchs EM, Paquet A, Lie Y, Sherwood T, Horvat R, Singer CF, Winslow J, Weidler JM, Huang W, Lipton A. Bates M, et al. Among authors: sperinde j. Ann Oncol. 2011 Sep;22(9):2014-2020. doi: 10.1093/annonc/mdq706. Epub 2011 Feb 2. Ann Oncol. 2011. PMID: 21289364 Free article.
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
Desmedt C, Sperinde J, Piette F, Huang W, Jin X, Tan Y, Durbecq V, Larsimont D, Giuliani R, Chappey C, Buyse M, Winslow J, Piccart M, Sotiriou C, Petropoulos C, Bates M. Desmedt C, et al. Among authors: sperinde j. Diagn Mol Pathol. 2009 Mar;18(1):22-9. doi: 10.1097/PDM.0b013e31818ebc69. Diagn Mol Pathol. 2009. PMID: 19214112
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M. Lipton A, et al. Among authors: sperinde j. Breast Cancer Res Treat. 2013 Aug;141(1):43-53. doi: 10.1007/s10549-013-2665-0. Breast Cancer Res Treat. 2013. PMID: 23959396 Free PMC article.
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA, Kaufman PA, Huang W, Krekow L, Savin M, Lawler WE, Zrada S, Starr A, Einhorn H, Schwartzberg LS, Adams JW, Lie Y, Paquet AC, Sperinde J, Haddad M, Anderson S, Brigino M, Pesano R, Bates MP, Weidler J, Bosserman L. Yardley DA, et al. Among authors: sperinde j. Breast Cancer Res. 2015 Mar 18;17(1):41. doi: 10.1186/s13058-015-0543-x. Breast Cancer Res. 2015. PMID: 25886996 Free PMC article.
Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.
Duchnowska R, Sperinde J, Czartoryska-Arłukowicz B, Myśliwiec P, Winslow J, Radecka B, Petropoulos C, Demlova R, Orlikowska M, Kowalczyk A, Lang I, Ziółkowska B, Dębska-Szmich S, Merdalska M, Grela-Wojewoda A, Żawrocki A, Biernat W, Huang W, Jassem J. Duchnowska R, et al. Among authors: sperinde j. Oncotarget. 2017 Oct 24;8(61):104149-104159. doi: 10.18632/oncotarget.22027. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262628 Free PMC article.
34 results